Related Experiment Videos
[Drug-induced autoimmune hemolytic anemia].
1Laboratoire Central d'Immunologie et d'Hématologie, Hôpital Saint-Antoine, Paris.
Presse Medicale (Paris, France : 1983)
|May 6, 1999
Summary
Certain drugs can trigger autoimmune hemolytic anemia by affecting autoantigens and the immune system. Methyldopa is one example, though severe reactions are rare.
Area of Science:
- Immunology
- Pharmacology
Context:
- Autoantibody production necessitates circumventing immune tolerance.
- Drug-induced autoimmune hemolytic anemia requires drugs to affect both autoantigens and the immune system.
Purpose:
- To review drugs that induce autoimmune hemolytic anemia.
- To discuss the mechanism of drug-induced autoantibody production.
Summary:
- Methyldopa, a hypotensive agent, can induce anti-Rh IgG, anti-nuclear, and anti-actin autoantibodies in 20% of patients, with clinically significant hemolysis in 1-2%.
- Other drugs implicated include levodopa, mefenamic acid, interferon-alpha, cyclosporin, and fludarabin.
- Management involves continuing the drug if asymptomatic, but discontinuation, transfusion, and corticosteroids are needed for patent hemolytic anemia.
Impact:
- Highlights the potential for drug-induced autoimmunity.
- Provides a list of causative agents and management strategies for clinicians.
- Emphasizes the importance of monitoring patients on specific medications.